Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly

NCT00461149 is registered in ClinicalTrials.gov with Federico II University as lead sponsor.

NCT NCT00461149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00461149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly
Lead sponsor
Federico II University
Phase
Phase 4
Overall status
Completed
Start date
January 31, 1995
Completion date
December 31, 2006
Enrollment
50
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly